Explore the Global Diamond-Blackfan Anemia (DBA) Syndrome Therapeutics Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Diamond-Blackfan Anemia (DBA) Syndrome Therapeutics Market

Key Insight

Demand for Diamond-Blackfan anemia (DBA) syndrome therapeutics will increase through 2036, with blood transfusions at 35.6% of the treatment segment in 2026. The market was valued at USD 5.20 billion in 2025 and is expected to reach USD 5.4 billion by 2026-end and USD 8.2 billion by 2036.

April 28, 2026

Anurag Sharma

298 Pages

Cite this Report

Diamond-Blackfan Anemia (DBA) Syndrome Therapeutics Market

https://www.futuremarketinsights.com/reports/diamond-blackfan-anemia-syndrome-therapeutics-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Acceleron Pharma
Beam Therapeutics Inc
Bluebird Bio
CRISPR Therapeutics AG
Editas Medicine
Global Blood Therapeutics
Magenta Therapeutics
Novartis
Regeneron Pharmaceuticals
L'Oréal
Vertex Pharmaceuticals Incorporated

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Diamond-Blackfan Anemia (DBA) Syndrome Therapeutics Market

Key Players

Similar Industry Reports